ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 561,13
0,00%
Dow Jones
39 169,52
0,13%
DAX
18 290,66
0,31%
Brent Oil
86,685
0,18%
Bitcoin
62 967,89
0,19%
Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Genenta Science SPA (GNTA)

  7. Genenta Science SPA (GNTA) Actualités

GNTA

Genenta Science (GNTA)

Genenta Science SPA
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:GNTA
DateHeureSourceTitreSymboleSociété
06/05/202412h25GlobeNewswire Inc.Genenta Welcomes New Directors John L. Cantello, Lauren H. Chung, Armon R. Sharei, and Todd WiderNASDAQ:GNTAGenenta Science SPA
12/02/202422h05Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:GNTAGenenta Science SPA
08/02/202411h00GlobeNewswire Inc.Genenta Demonstrated Reprogramming of the Tumor Microenvironment in GBM Patients, Paving the Way for Innovative Treatments of Solid TumorsNASDAQ:GNTAGenenta Science SPA
20/10/202322h15Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GNTAGenenta Science SPA
06/09/202313h00GlobeNewswire Inc.Genenta to Present at Upcoming Scientific and Investor ConferencesNASDAQ:GNTAGenenta Science SPA
28/07/202309h00GlobeNewswire Inc.Genenta Announces Ongoing Clinical Trial Progress and Proposed Expansion in Solid Tumor TreatmentsNASDAQ:GNTAGenenta Science SPA
29/06/202313h00GlobeNewswire Inc.The European Commission Grants Orphan Drug Designation to Temferon™ for Treatment of GliomaNASDAQ:GNTAGenenta Science SPA
25/05/202312h04Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:GNTAGenenta Science SPA
16/05/202313h00GlobeNewswire Inc.Genenta to Provide Update on Lead Product Temferon™NASDAQ:GNTAGenenta Science SPA
12/05/202323h13Edgar (US Regulatory)Securities Registration (foreign Private Issuer) (f-3)NASDAQ:GNTAGenenta Science SPA
01/05/202322h06Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:GNTAGenenta Science SPA
26/04/202313h00GlobeNewswire Inc.Genenta Announces Fiscal Year 2022 Financial Results and Annual Report on Form 20-F FilingNASDAQ:GNTAGenenta Science SPA
21/04/202323h23Edgar (US Regulatory)Annual and Transition Report (foreign Private Issuer) (20-f)NASDAQ:GNTAGenenta Science SPA
10/02/202312h10Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:GNTAGenenta Science SPA
27/10/202200h45TipRanksMaxim Group Remains a Buy on Genenta Science SpA Sponsored ADR (GNTA)NASDAQ:GNTAGenenta Science SPA
25/07/202212h00GlobeNewswire Inc.AmCham Italy and Genenta Science Announce the Bowling Green Bull InitiativeNASDAQ:GNTAGenenta Science SPA
15/06/200916h47PR Newswire (US)The following is an investment opinion release issued by EmergingStockReport.comNASDAQ:GNTA
15/05/200916h48PR Newswire (US)Stock Alerts on Market Movers: NGRN, RMBS, NVLS, LVS, GNTA, AN; Issued by Beacon EquityNASDAQ:GNTA
07/03/200901h36Dow Jones NewsGenta: FDA Favors Clinical Trial For Leukemia Drug GenasenseNASDAQ:GNTAGenta Inc.
07/03/200900h34Business WireFDA Appeal Decision Indicates that Genasense® Approval in Chronic Lymphocytic Leukemia Will Require Additional Confirmatory ...NASDAQ:GNTAGenenta Science SPA
13/02/200922h10Business WireGenta Incorporated Announces Fourth Quarter and Year End 2008 Financial Results and Corporate HighlightsNASDAQ:GNTAGenenta Science SPA
07/01/200919h02PR Newswire (US)Beacon Equity Issues Technical Trade Alerts on Newsworthy Market Movers: WLT, SSCC, FNSR, CHTR, STSI, GNTANASDAQ:GNTA
15/09/200814h05PR Newswire (US)Independent Monitoring Board Recommends Completion of Accrual to Genasense(R) Phase 3 AGENDA Trial in Advanced MelanomaNASDAQ:GNTA
07/08/200814h00PR Newswire (US)Genta Incorporated Announces Second Quarter 2008 Financial Results and Corporate HighlightsNASDAQ:GNTA
31/07/200814h00PR Newswire (US)Genta Announces Second Quarter 2008 Financial Results and Conference CallNASDAQ:GNTA
15/07/200815h20PR Newswire (US)BeaconEquity.com Issues TraderNotes on Active Stocks: CELI, UVSE, GSPG, GNTA, AAPL, IMMU, EXAS, EEENASDAQ:GNTA
14/07/200814h05PR Newswire (US)FDA Accepts Genta's NDA Amendment as Complete Response for Genasense(R) Treatment of Chronic Lymphocytic LeukemiaNASDAQ:GNTA
08/07/200817h00PR Newswire (US)BeaconEquity.com Issues TraderNotes on Active Stocks: REGRF, PASO, QMNM, UAUA, CBAK, SMOD, GNTA, YHOONASDAQ:GNTA
03/07/200816h20PR Newswire (US)BeaconEquity.com Issues TraderNotes on Active Stocks: ERII, EXTR, IDXX, NSTR, CMLS, JAKK, MPWR, GNTANASDAQ:GNTA
24/06/200814h00PR Newswire (US)Genta Updates Progress of its Phase 3 Trial of Genasense(R) in Patients with Advanced MelanomaNASDAQ:GNTA
 Showing the most relevant articles for your search:NASDAQ:GNTA

Dernières Valeurs Consultées

NYSE
MRK
Merck
EU
HO
Thales
EU
MC
Lvmh Moet Hennessy Louis...
COIN
BTCUSD
Bitcoin
EU
RI
Pernod Ricard
EU
BEL20
Bel 20
NYSE
JPM
JP Morgan Chase
EU
CS
Axa
NASDAQ
GOOGL
Alphabet
EU
GLE
Societe Generale
EU
BN
Danone
SPI
SP500
S&P 500
EU
SGO
Cie de SaintGobain
NASDAQ
MSFT
Microsoft
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés